HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prolonged remission of refractory lymphomatoid granulomatosis after autologous hemopoietic stem cell transplantation with post-transplantation maintenance interferon.

Abstract
Lymphomatoid granulomatosis (LYG) is a rare Epstein Barr virus (EBV)-associated lymphoproliferative disease. Even with combination chemotherapy, mortality is high. There is no standard therapy for relapsed or refractory disease. There is only one report in the literature of a complete remission with high-dose chemotherapy and autologous stem cell transplantation. This study presents the case of a patient with progressive LYG, who was successfully treated with autologous stem cell transplantation after conditioning with high-dose chemotherapy and total body irradiation. After transplantation, maintenance therapy with interferon alpha 2a was administered for 3.75 years. The patient remains well and in remission 8 years post-transplantation. This is the first report of a durable (>1 year) complete remission after high-dose chemotherapy and autologous stem cell transplantation in LYG. The role of high-dose chemotherapy and autologous stem cell transplantation in relapsed or refractory cases merits further evaluation. The exact place of interferon in treatment of LYG remains to be clarified but is promising.
AuthorsAnna Johnston, Luke Coyle, David Nevell
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 47 Issue 2 Pg. 323-8 (Feb 2006) ISSN: 1042-8194 [Print] United States
PMID16321865 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Combined Modality Therapy
  • Disease Progression
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Interferon alpha-2
  • Interferon-alpha (administration & dosage, therapeutic use)
  • Lung Neoplasms (diagnosis, etiology, therapy)
  • Lymphomatoid Granulomatosis (complications, diagnosis, therapy)
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Remission Induction (methods)
  • Transplantation, Autologous
  • Treatment Outcome
  • Whole-Body Irradiation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: